Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Myeloproliferative Disorders 1Dermoid Cyst 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anemia 1

Interventions

Oxaliplatin 166Capecitabine 112Fluorouracil 95Docetaxel 85Cisplatin 84S 1 (combination) 83Leucovorin 64Paclitaxel 58Irinotecan 56pembrolizumab 36sintilimab 34Trastuzumab 34apatinib 30Bevacizumab 21Surgical Procedures, Operative 19Radiotherapy 19titanium silicide 17camrelizumab 17Nivolumab 17Ramucirumab 16Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 14Folfox protocol 14Epirubicin 14tislelizumab 13Neoadjuvant Therapy 12Cetuximab 12XELOX 10Tegafur 10Carboplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Stomach Neoplasms × vactosertib × Clear all
NCT04893252 2022-11-30

Vactosertib and Durvalumab in Gastric Cancer

National Cancer Center, Korea

Phase 2 Unknown
55 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04656002 2022-06-15

As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Samsung Medical Center

Phase 2 Unknown
43 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡